Exhibit 99.2
CORPORATE PRESENTATION Frank Bedu-Addo Ph.D. President & CEO MARCH 2020
2 Forward-Looking Statements This presentation contains forward-looking statements about PDS
Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market
opportunities. All statements other than statements of historical facts included in this presentation are forward-looking statements. The words “anticipates,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “intends,”
“likely,” “will,” “should,” “to be,” and any similar expressions or other words of similar meaning are intended to identify those assertions as forward-looking statements. These forward-looking statements involve substantial risks and
uncertainties that could cause actual results to differ materially from those anticipated.Factors that may cause actual results to differ materially from such forward-looking statements include those identified under the caption “Risk Factors”
in the documents filed with the Securities and Exchange Commission from time to time, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable law or regulation, PDSB undertakes no obligation to update the forward-looking statements included in this
presentation to reflect subsequent events or circumstances.
PDS Biotechnology leadership team has demonstrated success in the development and commercialization
of leading pharmaceutical products 3 Frank Bedu-Addo, PhDChief Executive Officer Lauren V. Wood, MDChief Medical Officer Gregory Conn, PhDChief Scientific Officer Senior executive experience with management of strategy and execution at
both large pharma and biotechsNotable drug development:Abelcet® (Liposome Company/ Elan)PEG-Intron® (Schering-Plough/ Merck) >30 years of translational clinical research experienceFormer Director of Clinical Research at the National Cancer
Institute Center for Cancer Research (Cancer Vaccine Branch) Co-founder>35 years of drug development experience In-depth experience with biotech drug discovery, product development and manufacturing
PDS Biotech is well-poised to transform cancer treatment by fulfilling the promise of
immuno-oncology 4 Clinical studies in areas of high unmet medical need supported by leaders in the field 4 Diversified pipeline 3 Demonstrated potential for strong clinical efficacy and durability of the response with minimal
toxicity 2 Powerful T-cell activating immunotherapy platform 1
PDS Biotech is a clinical stage biotechnology company developing a pipeline of immunotherapies based on
the proprietary Versamune® platform 5 Versatile and potent T-cell-activating platformClinically validated induction of active antigen-specific killer and helper T-cells in vivoPromising clinical efficacy results in early trials of PDS0101
monotherapy with good safety and no dose limiting toxicities Publicly listed via reverse merger with Edge Therapeutics in March 2019~15 employees with headquarters in Princeton, NJ14.5M shares outstanding with $21.7M in cash* PDS0101 (Phase
2): HPV-associated cancers (Anal, head & neck, cervical etc.)PDS0102 (Formulation complete): Prostate, breast cancersPDS0103: Ovarian, breast, colorectal and lung cancersPDS0104: Melanoma Pipeline Versamune® Platform Corporate
Overview * February 28, 2020
6 Reference: Data on file. PDS Biotech’s pipeline combines the Versamune® platform with proprietary
& validated tumor antigens across several cancer types
Versamune® Platform
v Versamune® is based on proprietary, positively charged and immune activating lipids that form
spherical nanoparticles in aqueous media The nanoparticles are sized to mimic viruses, which promotes excellent uptake by dendritic cells of the immune systemActivates the important Type I interferon immunological signaling pathwayVersamune®
promotes the activation and maturation of dendritic cells, which then migrate to the lymph nodes Versamune® is a proprietary T-cell activating platform engineered to induce a robust, targeted anti-tumor response in
vivo 8 Water-insolubleFatty acids/hydrocarbon chains Water-soluble and positively charged head-group coats the particle surface R-enantiomer of 1,2-dioleoyl-trimethyl-ammonium-propane (R-DOTAP)
Inability to perform necessary steps to induce a therapeutic T-cell response in-vivo Versamune® design
and novel immunological mechanisms of action promote a powerful anti-tumor T-cell response Versamune® has demonstrated the potential to overcome the challenges of immunotherapy 9 Challenges of Immunotherapy How Versamune® May Overcome
the Challenge Inability to alter the tumor’s immunosuppressive microenvironment limits T-cell efficacy Ability to alter the tumor’s microenvironment de-camouflages the tumors allowing effective killing of the tumor by activated
T-cells Mechanistic limitations have resulted in lack of therapeutic benefit in human studies Mechanism of action associated with regression of disease in human studies (PDS0101 monotherapy) Reference: Gandhapudi SK, Ward M,
Bush JPC, Bedu-Addo F, Conn G, Woodward JG. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536.
Greater quantity and quality of Versamune®-induced killer T-cells may result in unique ability to
eradicate HPV-positive tumors after a single dose 10 Produces > 10-fold number of highly potent (polyfunctional) killer T-cells vs. other T-cell technologies Single treatment dose Results typical of current topclinical-stage HPV cancer
vaccines Tumor rechallenge at Day 60; complete and sustained cure of cancer *Adjuvant = cytokine GMCSFReferences: J. Immunology, 2019 (202), 1215; Studies in TC-1 tumor model with other immunotherapies reported in: Vaccine 2009, January
14, 27 (3): 431; Science Translational Medicine 2016, 13 April, Vol 8 Issue 334; Vaccine 2009, August 3, 27 (33): 5706
PDS0101
12 PDS0101 is designed to treat cancers caused by human papillomavirus (HPV) Approximately 43,000
patients are diagnosed with HPV-associated cancers each year, a number unlikely to be impacted by increased use of HPV preventive vaccines in the next decade References: Markowitz et al. 2016. Centers for Disease Control and Prevention. 2018.
Oropharyngeal (head & neck) cancers >18,000 cases annuallyMost common HPV-cancer in men,90% of cases are HPV16-specificIncidence increasingCervical cancer~12,000 cases annuallyMost common HPV-cancer in women,50-60% of cases are
HPV16-specificIncidence steadyInitial market research suggests market penetration of ~20% is reasonable for PDS0101 PDS0101 combines the utility of the Versamune® platform with a proprietary mix of HPV16 antigens, the most virulent high-risk
HPV type and by far the most prevalent in patients with HPV-associated cancer Females (24,391) Males (18,280)
13 The combination of Versamune® and a proprietary antigen is engineered for simplicity and ease of
administration Vials of HPV16 mix (L)and Versamune® (R) Versamune® formulationis mixed before injection* Delivered viasubcutaneous injection *Electron microscopy picture
14 PDS0101 Phase 1 clinical trial: Unique in vivo demonstration of high levels of HPV-specific killer
T-cells in circulating blood 14x 24x Total Activated T-Cells 26x Order of magnitude increase over baseline Versamune® Dose Reference: Data on file. INF-γ Elispot Granzyme-b Elispot Clinical Study Results in Patients with
CINImmunogenicity at Day 14Defined dose for Phase 2 studies (3mg)No dose-limiting toxicities Clinical study results successfully demonstrate translation of Versamune®’s multi-functional mechanism of action between pre-clinical models and
humans
15 Follow-up of patients in PDS0101 Phase 1 study demonstrated promising clinical responses at all three
tested doses A post-hoc, retrospective analysis, demonstrated complete lesion regression in at least 60% of evaluable patients (6/10) as early as 1-3 months after treatmentNo lesion recurrence occurred within the 2-year evaluation
periodSpontaneous regression of CIN1 occurs in about 44% of patients over a 2-year duration* These results were remarkably positive as most patients were infected with multiple high-risk HPV typesTwo patients who had regression by cytology were
not considered clinical responders:The first regressed to atypical cells of undetermined significance at the first post-treatment evaluation (3 months) but HPV detectedThe second had complete regression by cytology at the first post-treatment
evaluation (3 months) but had residual CIN by colposcopy Reference: Stefani C. et al, 2014, European Review for Medical and Pharmacological Sciences, 18: 728-733
Checkpoint inhibitors have shown confirmed clinical efficacy and have demonstrated clinical benefit in
late stage cancerCheckpoint inhibitors block a key immunological defense mechanism for cancer cells, and are reported to work primarily in patients whose immune systems are already generating tumor-attacking CD8+ killer T-cells
pre-treatmentUsing various tumor-specific proteins (antigens), Versamune® has demonstrated the unique ability to generate large and superior numbers of CD8+ killer T-cells that effectively recognize and kill antigen-expressing cancer cells in
pre-clinical and human clinical studies PDS Biotech clinical strategy in advanced cancer is to focus on efficiency and risk mitigation to proof of concept 16 Versamune®-based immunotherapies are being developed as combination therapies to
exploit the demonstrated synergies between Versamune® and other anti-cancer agents PDS Biotech is developing a new generation of advanced cancer treatments combining Versamune®-based immunotherapies with checkpoint inhibitors and other
standard of care therapies
The robust T-cell response induced by Versamune® results in the potential for enhancement of efficacy of
checkpoint inhibitors in immune suppressive B16 melanoma 17 Early clinical studies showed the checkpoint inhibitor to be ineffective in treating B16 melanoma, a notoriously difficult model to treat. Versamune® + TRP2 melanoma antigen
(sub-optimal levels) promotes infiltration of active killer T-cells into tumors, strong synergy with the checkpoint inhibitor, and significantly enhanced anti-tumor efficacy Reference: Gandhapudi SK, Ward M, Bush JPC, Bedu-Addo F, Conn G,
Woodward JG. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536. CD4+ helper T-cell CD8+ killer
T-cell
18 PDS0101 is the only compound selected by Merck for evaluation in combination with KEYTRUDA® as first
line cancer therapy PDS0101 + KEYTRUDA®Keytruda® first immunotherapy approved as standard of care for first line treatment of cancer (recurrent or metastatic head and neck cancer)PDS0101 first T-cell activating immunotherapy to demonstrate
both high levels of circulating CD8+ killer T-cells and therapeutic benefit as monotherapyUnique immuno-oncology combination addressing first-line treatment of cancerValidation of both efficacy and safety of PDS0101Anticipated advantages of
combining PDS0101 with standard of care: Mitigated riskPotential enhanced rates of recruitmentPotential for rapid market penetration and market leadership Initiate Phase 2 in 1H 2020
19 PDS Biotechnology-sponsored study with KEYTRUDA ® supplied by MerckPrimary endpoints: Efficacy,
safety and tolerabilityStudy design: Phase 2 open-label studyInclusion criteria: Recurrent/metastatic head and neck cancer and HPV16 infectionClinical Trial Identifier: NCT04260126 A Phase 2 study of PDS0101 in combination with KEYTRUDA ® in
first-line treatment of recurrent/metastatic head and neck cancer is planned for 1H 2020 Followed by open label SOC with KEYTRUDA® until disease progression or intolerance patients = 96 KEYTRUDA®
alone Combination of PDS0101 and KEYTRUDA® 200 mg IV KEYTRUDA® every 21 days in combinationwith 3 mg SC PDS0101 at cycles 1, 2, 3, 4 and 12 Expected data reads:Safety analysis of first 12 patients after Cycle 1: 4Q 2020Interim analysis
planned: 2H 2021
20 Investigator-Led Phase 2 studies of PDS0101 in combination therapy will evaluate efficacy and safety
in treatment of advanced HPV cancers Funded By Phase 2 Open Label Study (Safety and Efficacy) Important Considerations Expected Initiation Advanced HPV-associated malignancies – all typesTriple combination with EMD Serono’s M7824 and
NHS-IL1229 subjectsClinical Trial Identifier: NCT04287868 NCI selection and confirmation of synergies with PDS0101All three agents have demonstrated efficacy as monotherapies in early trials 1H 2020 Advanced, localized cervical cancer
(Stage IIb-IVa)Combination with chemo-radiotherapy (CRT-standard of care) 35 subjects T-cell induction has strong potential to enhance CRT anti-cancer efficacyMitigated riskPotential for rapid market penetration and market leadership 1H
2020 Leading Cancer Research Institute: TBA
PDS0102
22 PDS0102 combines a proven NCI-developed TARP antigen with Versamune® to promote the robust induction
of prostate- and breast-specific killer T-cells PDS Biotech collaboration with the National Cancer Institute (NCI)The TARP antigen was discovered by the NCI to be present in over 85% of prostate cancers and 50% of breast cancersThe NCI
demonstrated that the TARP antigen is recognized by T-cells of late-stage cancer patients, with vaccination resulting in a significant lowering of tumor growth rate*PDS Biotech is combining the TARP antigen with Versamune® (PDS0102) to
potentially promote more effective induction of prostate and breast-specific killer T-cells and altering of the tumor microenvironmentIn on-going pre-clinical studies Versamune®, has demonstrated the ability to significantly enhance the immune
system’s ability to generate TARP-specific killer T-cells Reference: Wood LV et al, Oncoimmunology, 2016, Vol. 5 (8)
Intellectual Property and Financials
24 Intellectual property provides multiple layers of technology and product protection for
Versamune®-related products through mid-2030s Versamune® and associated patents are owned and licensed by PDS BiotechPatents cover methods and compositions stimulating/promoting an immune response with Versamune® technology in various forms
and mechanisms through 2034Use of specific cationic lipids to induce an immune responseCompositions and use of any cationic lipid to activate MAP kinaseCompositions and use of R-DOTAP to induce immune responseMicellar antigen + cationic lipids
compositions (US still ongoing) Compositions of R-DOTAP with GM-CSF to reduce immune suppressive myeloid derived suppressor cells in the tumorFive issued international patent families (including Europe and Japan)
PDS Biotech is in a financial position to support critical near-term
milestones 25 Nasdaq: PDSB Shares Outstanding* 14.5M Cash* $21.7M Share Price** $0.67 Market Cap** $9.7M Debt* --- 1H 2020: Initiation of PDS Biotech-Merck Phase 2 combination study in head and neck cancer 1H 2020: Initiation of
PDS Biotech-NCI Phase 2 combination study in advanced HPV-associated cancers1H 2020: Initiation of Partnered Phase 2 combination study in advanced cervical-cancer 3Q 2020: Complete formulation of PDS0102 *February 28, 2020 **March 20,2020
PDS Biotech is well-poised to transform cancer treatment by fulfilling the promise of
immuno-oncology 26 Clinical studies in areas of high unmet medical need supported by leaders in the field 4 Diversified pipeline 3 Demonstrated potential for strong clinical efficacy and durability of the response with minimal
toxicity 2 Powerful T-cell activating immunotherapy platform 1
